FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

AUROPHARMA

743.95
-15.5 (-2.04%)
Updated 03:29 05/06 IST

AUROPHARMA Buy or Sell - FrontPage Forums

3 Users have submitted 3 trade ideas of Rs. 247,387.5 for AUROPHARMA
Disclaimer
67% Bullish
33% Bearish

AUROPHARMA Ratings

Long term AUROPHARMA rating by FrontPage users
4.5/5 (26 Ratings)
Find answers to all your questions on live AUROPHARMA message board: Is AUROPHARMA buy or sell? Should I buy AUROPHARMA shares? Why are AUROPHARMA shares falling? Should I invest in AUROPHARMA stock?

AUROPHARMA Share Price Discussion

Reputation: 3,179 • Today 5:51 AM
Buy Aurobindo Pharma, target price Rs 880: Motilal Oswal
The brokerage raised the companys EPS estimate for FY20/FY21 by 4.4 per cent/9 per cent, and expects a 9 per cent earnings CAGR over FY20–22, led by new launches and increased market share in key markets,
The Economic Times
Like
Reply
Reputation: 3,179 • Today 5:33 AM
Buy Aurobindo Pharma; target of Rs 870: ICICI Securities
ICICI Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 870 in its research report dated June 04, 2020.
Moneycontrol
Like
Reply

AUROPHARMA - chart - 867288
AURO PHARMA GOOD SHORTING CANDIDATE AS PER ELLIOT WAVE STUDY
VIEW GETS NEGATED OF RECENT PEAK BREAKS OUT,,
DOWN SIDE 10-13% POSSIBLE
1
Reply
Reputation: 19,103 • Today 3:32 AM

Type
Buy
Instrument
AUROPHARMA
Entry Price
₹763.85
Price@Trade
₹763.85
Target Price
₹780
Stop Price
₹759
Valid Till
Jun 5, 2020 3:20 AM
Margin
₹7,638.5 approx for 10 Qty
Status
Stoploss Hit
Exit Price
₹759
Net P&L
-₹48.5 (-0.63%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Today 3:42 AM

Update
Stoploss Hit
Exit Price
₹759
Reputation: 3,179 • Today 3:18 AM
Aurobindo Pharma share price gains 2% after CLSA raises target price
CLSA increased FY21-22 EPS estimates by 8-10%.
Moneycontrol
Like
Reply
Reputation: 3,179 • Today 3:18 AM
Buy Aurobindo Pharma; target of Rs 786: Emkay Global Financial
Emkay Global Financial is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 786 in its research report dated June 03, 2020.
Moneycontrol
Like
Reply
Reputation: -3,636 • Today 3:05 AM

Type
Sell
Instrument
AUROPHARMA JUN20 FUT
Entry Price
₹968
Price@Trade
₹767.7
Target Price
₹957
Stop Price
₹976
Valid Till
Jun 5, 2020 3:20 AM
Margin
₹285,719.5 approx for 1000 Qty
Status
Exited before entry
Like
Reply (1)
Latest replies
Ashish Tiwari @sifm
Today 3:48 AM

Update
Exited before entry
Price @ Update
₹760.05
Reputation: -15,697 • Today 1:41 AM

CLSA On Aurobindo
Maintain Buy, TP raised to Rs 920 from Rs 790
Strong All-around Performance
Launch Momentum In US & EU Remains Strong
Results Well Ahead Of Est
Volume Share Gains In US & Stocking Benefit In EU Drove Margin
Like
Reply
A
Reputation: 635 • Yesterday 8:51 AM
Arvind in AUROPHARMA
New trade: Sell AUROPHARMA JUN20 FUT, CMP@763.9...
Like
Reply
A
Reputation: 1,013 • Yesterday 8:33 AM

Type
Buy
Instrument
AUROPHARMA
Entry Price
₹765.5
Price@Trade
₹766
Target Price
₹780
Stop Price
₹751
Valid Till
Jun 11, 2020 3:20 AM
Margin
₹382,750 approx for 500 Qty
Status
Exited
Exit Price
₹768.75
Net P&L
+₹1,625 (+0.42%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Yesterday 8:35 AM

Update
Trade Entered
Entry Price
₹765.5
Abhi @advait
Today 3:02 AM

Update
Exited
Exit Price
₹768.75
Net P&L
+₹1,625 (+0.42%)
A
Reputation: 635 • Yesterday 7:55 AM

Type
Sell
Instrument
AUROPHARMA JUN20 FUT
Entry Price
₹764
Price@Trade
₹763.95
Target Price
₹752
Stop Price
₹771
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹573,853 approx for 2000 Qty
Status
Validity Over
Exit Price
₹759.65
Net P&L
+₹8,700 (+1.52%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Yesterday 7:56 AM

Update
Trade Entered
Entry Price
₹764
TrackerBot @trackerbot
Yesterday 8:50 AM

Update
Validity Over
Exit Price
₹759.65
Net P&L
+₹8,700 (+1.52%)
J
Reputation: -22,725 • Yesterday 7:25 AM

Type
Buy
Instrument
AUROPHARMA JUN20 FUT
Entry Price
₹766.95
Price@Trade
₹766.95
Target Price
₹805
Stop Price
₹745
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹287,443.25 approx for 1000 Qty
Status
Stoploss Hit
Exit Price
₹745
Net P&L
-₹21,950 (-7.64%)
1
Reply (1)
Latest replies
TrackerBot @trackerbot
Today 8:34 AM

Update
Stoploss Hit
Exit Price
₹745
Reputation: 3,179 • Yesterday 7:11 AM
Buy Aurobindo Pharma, target price Rs 870: ICICI Securities
The brokerage has raised its earnings estimates by 5-6 per cent to factor in higher revenue in US & emerging markets with better gross margin.
The Economic Times
Like
Reply
Reputation: 3,179 • Yesterday 6:53 AM
Aurobindo Pharm Standalone March 2020 Net Sales at Rs 3,620.32 crore, up 10.36% Y-o-Y
Moneycontrol
Like
Reply
Reputation: 3,179 • Yesterday 6:53 AM
Aurobindo Pharm Consolidated March 2020 Net Sales at Rs 6,158.43 crore, up 16.37% Y-o-Y
Moneycontrol
Like
Reply
DECENT PROFITS in AUROPHARMA
active #AUROPHARMA
Like
Reply
T
Reputation: 14,670 • Yesterday 6:33 AM

Type
Buy
Instrument
AUROPHARMA JUN20 760 CE
Entry Price
₹42
Price@Trade
₹45.2
Target Price
₹55
Stop Price
₹38
Valid Till
Jun 5, 2020 3:20 AM
Margin
₹42,000 approx for 1000 Qty
Status
Exited before entry
Like
Reply (1)
Latest replies
Tulasi @Tulasi9
Yesterday 7:04 AM

Update
Exited before entry
Price @ Update
₹45.5
Reputation: 3,179 • Yesterday 5:51 AM
Share market update: Pharma shares up; Lupin rises over 2%
The Nifty Pharma index was trading 1.11 per cent up at 9973.95.
The Economic Times
Like
Reply
Reputation: 3,179 • Yesterday 5:46 AM
MOFSL view on Aurobindo, Tata Motors & other auto stocks
‘If Tata Motors raise money, the capital dilution could be very significant
The Economic Times
Like
Reply
DECENT PROFITS in AUROPHARMA
New trade: Buy AUROPHARMA JUN20 FUT, CMP@758.95...
Like
Reply
DECENT PROFITS in AUROPHARMA
Trade entered: Sell AUROPHARMA JUN20 FUT @756.0...
Like
Reply

Type
Sell
Instrument
AUROPHARMA JUN20 FUT
Entry Price
₹756.05
Price@Trade
₹756.05
Target Price
₹730
Stop Price
₹765
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹287,350 approx for 1000 Qty
Status
Stoploss Hit
Exit Price
₹765
Net P&L
-₹8,950 (-3.11%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 5:46 AM

Update
Stoploss Hit
Exit Price
₹765

Type
Buy
Instrument
AUROPHARMA JUN20 FUT
Entry Price
₹761
Price@Trade
₹758.95
Target Price
₹770
Stop Price
₹754
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹283,334 approx for 1000 Qty
Status
Exited before entry
Like
Reply (1)
Latest replies

Update
Exited before entry
Price @ Update
₹757.1

Type
Sell
Instrument
AUROPHARMA
Entry Price
₹758
Price@Trade
₹758
Target Price
₹696.55
Stop Price
₹788.35
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹100,056 approx for 132 Qty
Status
Validity Over
Exit Price
₹758.15
Net P&L
-₹19.8 (-0.02%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 8:50 AM

Update
Validity Over
Exit Price
₹758.15
Net P&L
-₹19.8 (-0.02%)
Reputation: 3,179 • Yesterday 5:06 AM
Aurobindo Pharma surges 5% on strong Q4 results
“Strong execution and debt reduction should continue to drive the stocks outperformance. Aurobindo Pharma is one of our top large cap picks and a significant overweight,” said Emkay Global.
The Economic Times
Like
Reply

Type
Sell
Instrument
AUROPHARMA
Entry Price
₹764.15
Price@Trade
₹764.15
Target Price
₹701.4
Stop Price
₹793.2
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹99,339.5 approx for 130 Qty
Status
Validity Over
Exit Price
₹758.15
Net P&L
+₹780 (+0.79%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 8:50 AM

Update
Validity Over
Exit Price
₹758.15
Net P&L
+₹780 (+0.79%)
Reputation: 1,590 • Yesterday 4:31 AM
Ajay Singh in AUROPHARMA
#AUROPHARMA Weekly chart of auropharma Target...

790 (max)
Perfect analysis exist😁
Made 52 week high
Can book profit now 😊👍🏻👍🏻
3
Reply

Type
Buy
Instrument
AUROPHARMA
Entry Price
₹769.25
Price@Trade
₹769.25
Target Price
₹790
Stop Price
₹761
Valid Till
Jun 5, 2020 3:20 AM
Margin
₹230,775 approx for 300 Qty
Status
Stoploss Hit
Exit Price
₹761
Net P&L
-₹2,475 (-1.07%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 4:53 AM

Update
Stoploss Hit
Exit Price
₹761
M
Reputation: 7,002 • Yesterday 3:28 AM

Type
Buy
Instrument
AUROPHARMA
Entry Price
₹773.95
Price@Trade
₹773.95
Target Price
₹900
Stop Price
₹700
Valid Till
Jul 3, 2020 3:20 AM
Margin
₹193,487.5 approx for 250 Qty
Status
Active
Like
Reply
Reputation: -3,636 • Yesterday 3:25 AM

Type
Buy
Instrument
AUROPHARMA JUN20 FUT
Entry Price
₹776
Price@Trade
₹775.5
Target Price
₹790
Stop Price
₹770
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹283,894.5 approx for 1000 Qty
Status
Stoploss Hit
Exit Price
₹770
Net P&L
-₹6,000 (-2.11%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Yesterday 3:26 AM

Update
Trade Entered
Entry Price
₹776
TrackerBot @trackerbot
Yesterday 3:32 AM

Update
Stoploss Hit
Exit Price
₹770
Reputation: 3,179 • Yesterday 3:23 AM
Aurobindo Pharma share price hits 52-week high on better Q4 numbers; Credit Suisse gives target of Rs 665
Revenue from operations grew by 16.4 percent to Rs 6,158.4 crore during the quarter.
Moneycontrol
Like
Reply

Type
Buy
Instrument
AUROPHARMA JUN20 780 CE
Entry Price
₹41.9
Price@Trade
₹41.9
Target Price
₹65
Stop Price
₹24
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹41,900 approx for 1000 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
AUROPHARMA
Entry Price
₹778  ₹776.2
Price@Trade
₹772
Target Price
₹799
Stop Price
₹761
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹232,860 approx for 300 Qty
Status
Stoploss Hit
Exit Price
₹761
Net P&L
-₹4,560 (-1.96%)
Like
Reply (3)
Latest replies
Trading Calls @tradingcalls
Yesterday 3:21 AM

Update
Entry Price Modified
Price @ Update
₹776.2
Original Entry Price
₹778
New Entry Price
₹776.2
TrackerBot @trackerbot
Yesterday 3:22 AM

Update
Trade Entered
Entry Price
₹776.2
TrackerBot @trackerbot
Yesterday 4:53 AM

Update
Stoploss Hit
Exit Price
₹761
DECENT PROFITS
if aurooharma cross 957 it will up tto 980

780 done ❤❤❤❤❤❤❤🎯🎯🎯🎯🎯
Like
Reply

Buy auropharma 740 pe @25.35 tgt 29 sl 24.90
29.25🔥🔥
Like
Reply (1)
Latest replies
Intraday trading @intradaytrading
Yesterday 3:10 AM

30🔥🔥
Reputation: -1,123 • Yesterday 2:59 AM

Type
Buy
Instrument
AUROPHARMA JUN20 FUT
Entry Price
₹786
Price@Trade
₹788.65
Target Price
₹800
Stop Price
₹780
Valid Till
Jun 11, 2020 3:20 AM
Margin
₹284,232.25 approx for 1000 Qty
Status
Stoploss Hit
Exit Price
₹780
Net P&L
-₹6,000 (-2.11%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Yesterday 3:00 AM

Update
Trade Entered
Entry Price
₹786
TrackerBot @trackerbot
Yesterday 3:02 AM

Update
Stoploss Hit
Exit Price
₹780

Type
Buy
Instrument
AUROPHARMA JUN20 FUT
Entry Price
₹780  ₹778
Price@Trade
₹782.45
Target Price
₹790
Stop Price
₹772
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹284,034.5 approx for 1000 Qty
Status
Target Achieved
Exit Price
₹790
Net P&L
+₹12,000 (+4.22%)
Like
Reply (4)
Latest replies

Update
Entry Price Modified
Price @ Update
₹782.55
Original Entry Price
₹780
New Entry Price
₹783

Update
Entry Price Modified
Price @ Update
₹780.15
Original Entry Price
₹783
New Entry Price
₹778
TrackerBot @trackerbot
Yesterday 2:54 AM

Update
Trade Entered
Entry Price
₹778
TrackerBot @trackerbot
Yesterday 2:57 AM

Update
Target Achieved
Exit Price
₹790
A
Reputation: 3,278 • Yesterday 2:51 AM

Type
Buy
Instrument
AUROPHARMA
Entry Price
₹777
Price@Trade
₹780
Target Price
₹782
Stop Price
₹772
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹777 approx for 1 Qty
Status
Target Achieved
Exit Price
₹782
Net P&L
+₹5 (+0.64%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Yesterday 2:52 AM

Update
Trade Entered
Entry Price
₹777
TrackerBot @trackerbot
Yesterday 2:52 AM

Update
Target Achieved
Exit Price
₹782

INDIA GOVERNMENT APPROVES SETTING UP OF AN EMPOWERED GROUP OF SECRETARIES (EGOS) & PROJECT DEVELOPMENT CELLS (PDCS) IN MINISTRIES/DEPARTMENTS FOR ATTRACTING INVESTMENTS IN INDIA: UNION MINISTER PRAKASH JAVADEKAR
INDIA TO DEREGULATE FOOD STUFFS INCLUDING CEREALS, EDIBLE OILS, OILS...
Read more...
Like
Reply

AUROPHARMA - 860252
AuroPharma results good performance all around
Like
Reply
Reputation: 3,179 • Jun 3 2:28 AM
Trade Setup for Thursday: Top 15 things to know before Opening Bell
The key support level for Nifty is placed at 10,005.93, followed by 9,950.37. If the index moves up, key resistance levels to watch out for are 10,146.63 and 10,231.77.
Moneycontrol
Like
Reply
Reputation: 3,179 • Jun 3 1:58 AM
Aurobindo Pharma's net jumps by 45% to Rs 850 crore in Q4
For the full year 2019-20, revenue from operations was at Rs 23,098.5 crore witnessing a growth of 18.1 percent over 2018-19.
Moneycontrol
Like
Reply
Reputation: 13,291 • Jun 3 12:57 PM

AUROBINDO PHARMA: Q4 CONS NET PROFIT 8.5B RUPEES VS 5.85B (YOY); EST 7.1B || Q4 CONS REVENUE 61.58B RUPEES VS 52.92B (YOY)
1
Reply

AUROBINDO PHARMA: Q4 CONS NET PROFIT 8.5B RUPEES VS 5.85B (YOY); EST 7.1B || Q4 CONS REVENUE 61.58B RUPEES VS 52.92B (YOY)
1
Reply (3)
Latest replies
Slacktalk @slacktalk
Yesterday 1:04 AM

What is your take on Aurobindo for today?

Gap up. Dont buy at opening
Slacktalk @slacktalk
Yesterday 2:20 AM

Thank you
DECENT PROFITS
759 from 749
1
Reply
Reputation: -895 • Jun 3 7:53 AM

Type
Buy
Instrument
AUROPHARMA JUN20 FUT
Entry Price
₹752.8
Price@Trade
₹752.8
Target Price
₹770
Stop Price
₹747
Valid Till
Jun 10, 2020 3:20 AM
Margin
₹281,668 approx for 1000 Qty
Status
Target Achieved
Exit Price
₹770
Net P&L
+₹17,200 (+6.11%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Yesterday 2:46 AM

Update
Target Achieved
Exit Price
₹770
TEAM AD @teamad
Yesterday 2:46 AM

Auro pharma boom rocket
18000+ profit
Reputation: 2,933 • Jun 3 6:58 AM

Type
Buy
Instrument
AUROPHARMA
Entry Price
₹756
Price@Trade
₹754.5
Target Price
₹766
Stop Price
₹746
Valid Till
Jun 3, 2020 3:20 AM
Margin
₹226,800 approx for 300 Qty
Status
Validity Over
Exit Price
₹750.75
Net P&L
-₹1,575 (-0.69%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jun 3 7:04 AM

Update
Trade Entered
Entry Price
₹756
TrackerBot @trackerbot
Jun 3 8:50 AM

Update
Validity Over
Exit Price
₹750.75
Net P&L
-₹1,575 (-0.69%)
DECENT PROFITS in AUROPHARMA
New trade: Buy AUROPHARMA JUN20 760 CE, CMP@35....
Like
Reply

Type
Sell
Instrument
AUROPHARMA
Entry Price
₹747
Price@Trade
₹746.75
Target Price
₹735
Stop Price
₹752
Valid Till
Jun 3, 2020 3:20 AM
Margin
₹373,500 approx for 500 Qty
Status
Stoploss Hit
Exit Price
₹752
Net P&L
-₹2,500 (-0.67%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jun 3 6:30 AM

Update
Trade Entered
Entry Price
₹747
TrackerBot @trackerbot
Jun 3 6:47 AM

Update
Stoploss Hit
Exit Price
₹752
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • AUROPHARMA - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization46,051.74
    Enterprise Value50,495.97
    Price to Earnings18.01
    Price to Book Value4.06
    Return on Capital Employed0.17
    Return on Equity0.18
    Face Value1
    Dividend Yield0.01
  • AUROPHARMA - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    22-Apr-20Nirmal BangAccumulate719
    21-Apr-20ICICIdirect.comBuy770
    21-Apr-20Prabhudas LilladherAccumulate702
    21-Apr-20Motilal OswalBuy745
    3-Apr-20Nirmal BangBuy484
    AUROPHARMA Brokerage Price Target
  • AUROPHARMA Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jun 5765775.6740.05744
    Jun 4774791753.55759.45
    Jun 3736758.7735.15750.4
    Jun 2729757.7725.35733.2
    Jun 1744746.45722725.65
  • AUROPHARMA Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹705.51
    30 Day Moving Average₹682.13
    50 Day Moving Average₹587.46
    100 Day Moving Average₹537.19
    200 Day Moving Average₹524.46
  • AUROPHARMA - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue10,2709,607.050.07
    Operating Profit2,6702,373.950.12
    Profit Before Tax2,3432,178.570.08
    Net Income1,8131,706.760.06
  • AUROPHARMA - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds11,3519,9830.14
    Total Liabilities6,7906,1970.1
    Total Assets18,14116,1800.12
  • AUROPHARMA - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity9142,457.2-0.63
    Cash from Investing Activity-981-1,542.05-0.36
    Cash from Financing Activity440-1,328.99-1.33
    Net Cash Flow372-413.84-1.9
  • AUROPHARMA - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.110.13
    Return on Equity0.180.2
    Return on Capital Employed0.170.19
  • AUROPHARMA - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.27
    3 Year CAGR Growth in Operating Profit0.19
    3 Year CAGR Growth in EBIDTA0.19
    3 Year CAGR Growth in Net Income0.2
    3 Yr CAGR Growth - Diluted EPS-0.4
  • AUROPHARMA - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.89
    5 Year CAGR Growth in Operating Profit1.79
    5 Year CAGR Growth in EBIDTA1.79
    5 Year CAGR Growth in Net Income2.66
    3 Yr CAGR Growth - Diluted EPS0.82
  • AUROPHARMA - Recent News

    keyboard_arrow_down
    NewsBot
    Today 5:51 AM
    Buy Aurobindo Pharma, target price Rs 880: Motilal Oswal
    The Economic Times
    NewsBot
    Today 5:33 AM
    Buy Aurobindo Pharma; target of Rs 870: ICICI Securities
    Moneycontrol
    NewsBot
    Today 3:18 AM
    Aurobindo Pharma share price gains 2% after CLSA raises target price
    Moneycontrol
    NewsBot
    Today 3:18 AM
    Buy Aurobindo Pharma; target of Rs 786: Emkay Global Financial
    Moneycontrol
    NewsBot
    Yesterday 7:11 AM
    Buy Aurobindo Pharma, target price Rs 870: ICICI Securities
    The Economic Times
    NewsBot
    Yesterday 6:53 AM
    Aurobindo Pharm Standalone March 2020 Net Sales at Rs 3,620.32 crore, up 10.36% Y-o-Y
    Moneycontrol
    NewsBot
    Yesterday 6:53 AM
    Aurobindo Pharm Consolidated March 2020 Net Sales at Rs 6,158.43 crore, up 16.37% Y-o-Y
    Moneycontrol
    NewsBot
    Yesterday 5:51 AM
    Share market update: Pharma shares up; Lupin rises over 2%
    The Economic Times
    NewsBot
    Yesterday 5:46 AM
    MOFSL view on Aurobindo, Tata Motors & other auto stocks
    The Economic Times
    NewsBot
    Yesterday 5:06 AM
    Aurobindo Pharma surges 5% on strong Q4 results
    The Economic Times
  • AUROPHARMA - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
  • AUROPHARMA - More Information

    keyboard_arrow_down

    Aurobindo Pharma Ltd:
    Aurobindo Pharma Limited is propagating its business in researching, developing, manufacturing, and selling of several pharmaceutical products in India. Producing a significant variation in oral and injectable generic formulations, and active pharmaceutical ingredients and manufacturing peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries.
    Along with providing custom research and producing services to biotech and pharmaceutical community the company is reigning over antibiotic, anti-retroviral, cardiovascular, central nervous system, gastroenterological, anti-diabetic, and anti-allergy areas. Besides that, the company is manufacturing proteins, vitamins, minerals, and supplements, sports drinks etc.
    The company is exporting its products to almost 150 countries, including the U.S. and Europe along with serving multinational companies. The company is amongst the largest producers of Ampicillin and Cloxacillin in India. Aurobindo Pharma Limited was established in 1986 as a private limited company and headquartered in Hyderabad, Andhra Pradesh, India.
    About Company Information:
    Aurobindo Pharma was converted to a public limited firm in the year of 1992, after six years from its inception. The company built A CMIC chloride manufacturing unit at Pashamylaram near Hyderabad in the same year. The company started to issue bonus shares in a ratio of 1:1, 2:1 and 7:20 in ’92, ’93 and ’94 respectively. In 1993 the company built up another two plants at Bollaram and Kukatpally near Hyderabad. In 1994, the company increased the capacity at Pondicherry Unit from 204 TPA to 300 TPA along with increasing the installed capacity of its Bollaram unit from 78 TPA to 84 TPA. An amalgamation took place between the company and Chaitanya Organics Pvt. Ltd. in April 1994.
    Glaxo (India), a subsidiary of the U.K. based multinational Glaxo went for an alliance with Aurobindo Pharma in 1997, which increased the number of capsules and bulk drug up to 300 million and 840 tons respectively. In 1998, the company introduced Auronim Suspension in its pediatric segment. In FY 1999-2000, the company added a large section of Cephalosporins (Oral & Sterile) and anti-viral along with macrolides, quinolones, semi-synthetic penicillin, formulating for both the domestic and export market.
    During 2001-02 79% stake in Ranit Pharma Company were acquired by Aurobindo Pharma Ltd. A 50:50 joint venture firm of the company, namely Citadel Aurobindo Biotech Ltd, launched Aztreonam, a Monabactam Beta-lactam antibiotics as a debut in the Indian Pharma Market, TREONAM being the brand name, in 2003. In 2005-06, the company intervened in the markets of USA & Europe, with participation in the PEPFAR program, initiated by the US Govt. In March 2007, the FDA (U.S.) finally approved the company’s Didanosine Oral Suspension (Pediatric Powder) 10 mg/ml.
    Aurobindo Pharma acquired Moore and Carmiooro, the high profile OTC brands from TAD in 2008. AstraZeneca, a leading biopharmaceutical company in the international market, had gone for an agreement with Aurobindo Pharma, for supplying solid dosage and sterile products in 2010. A deal took place between Aurobindo Pharma and National Pharmaceutical Group Corporation, China, for launching the subsidiary Aurobindo (Datong) BioPharma Co Ltd, China (ADBPL).
    In April 2014, Aurobindo Pharma declared the completion of several business operations of Europe’s Actavis plc, an internationally recognized pharmaceutical company, manufacturing and supplying generic, brand and biosimilar products. On November 2016, a subsidiary of Aurobindo Pharma Ltd in France, namely Arrow Generiques SAS, signed an agreement to gain the right, title and interest in its products Calcium and Calcium Vitamin D3 in the French market, including the use of Teva Pharmaceutical Industries OROCAL trademark.
    On January 2017, Aurobindo Pharma declared about setting up a binding agreement by and through its solely owned subsidiary, Agile Pharma B.V., Netherlands, for acquiring Generis Farmaceutica SA, a pharmaceutical company of Portugal, against a lump sum of 135 million Euro totally including net working capital of 21.7 million Euro. On February 2017, four-cell culture derived biosimilar products from T.L. Biopharmaceutical AG were acquired by Aurobindo Pharma as declared by the company.
    How Aurobindo Pharma Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Aurobindo Pharma Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Aurobindo Pharma Ltd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Bacil Pharma Ltd. BACPHA
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Brooks Laboratories Ltd. BROLAB
    Cipla Ltd. CIPLTD
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Earum Pharmaceuticals Ltd.
    Elder Health Care Ltd. ELDHEA
    Elder Pharmaceuticals Ltd. ELDPHA
    Elegant Pharmaceuticals Ltd. ELEPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Novartis India Ltd. NOVAIN
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Piramal Phytocare Ltd. PIRLIF
    Ranbaxy Laboratories Ltd. RANLAB
    Sanjivani paranteral Ltd. SANPAR
    Sanofi India Ltd. AVEPHA
    Sarvodaya Labs Ltd. SARLAB
    Sun Pharmaceutical Industries Ltd. SUN28
    TTK Healthcare Ltd. TTKHEA
    Venmax Drugs & Pharmaceuticals Ltd. YENDRU
    Venus Remedies Ltd. VENREM
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zim Laboratories Ltd. ZIMLAB
    Zora Pharma Ltd.[Amalgamated] ZORPHA
    Zota Healthcare Ltd. ZOTHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020